Class information for:
Level 2: NON SMALL CELL LUNG CANCER//XRCC1//GEFITINIB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
823 11253 37.4 83%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 3)


ID, lev.
above		 Publications Label for level above
217 46988 NON SMALL CELL LUNG CANCER//BRAIN METASTASES//LUNG CANCER

Classes in level below (level 1)


ID, lev. below Publications Label for level below
362 3515 GEFITINIB//ERLOTINIB//EGFR MUTATION
1328 2615 VINORELBINE//GEMCITABINE//ADVANCED NON SMALL CELL LUNG CANCER
2131 2278 XRCC1//XRCC3//XRCC1 GENE
8141 1215 PEMETREXED//MULTITARGETED ANTIFOLATE//NONSQUAMOUS
10101 1028 CRIZOTINIB//ANAPLASTIC LYMPHOMA KINASE//ALK
17170 550 ERCC1//RRM1//MED OVARIAN CANC SECT
35116 52 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 NON SMALL CELL LUNG CANCER Author keyword 669 26% 19% 2186
2 XRCC1 Author keyword 463 76% 3% 323
3 GEFITINIB Author keyword 428 47% 6% 671
4 ERLOTINIB Author keyword 351 45% 5% 590
5 ERCC1 Author keyword 323 70% 2% 270
6 PEMETREXED Author keyword 247 48% 3% 376
7 XRCC3 Author keyword 210 83% 1% 118
8 EGFR MUTATION Author keyword 209 58% 2% 241
9 LUNG CANCER Journal 196 21% 8% 845
10 NSCLC Author keyword 187 24% 6% 676

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class		 LCSH search Wikipedia search
1 NON SMALL CELL LUNG CANCER 669 26% 19% 2186 Search NON+SMALL+CELL+LUNG+CANCER Search NON+SMALL+CELL+LUNG+CANCER
2 XRCC1 463 76% 3% 323 Search XRCC1 Search XRCC1
3 GEFITINIB 428 47% 6% 671 Search GEFITINIB Search GEFITINIB
4 ERLOTINIB 351 45% 5% 590 Search ERLOTINIB Search ERLOTINIB
5 ERCC1 323 70% 2% 270 Search ERCC1 Search ERCC1
6 PEMETREXED 247 48% 3% 376 Search PEMETREXED Search PEMETREXED
7 XRCC3 210 83% 1% 118 Search XRCC3 Search XRCC3
8 EGFR MUTATION 209 58% 2% 241 Search EGFR+MUTATION Search EGFR+MUTATION
9 NSCLC 187 24% 6% 676 Search NSCLC Search NSCLC
10 CRIZOTINIB 172 65% 1% 162 Search CRIZOTINIB Search CRIZOTINIB

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 GEFITINIB 942 43% 15% 1682
2 ERLOTINIB 778 53% 9% 1039
3 EGFR MUTATIONS 548 62% 5% 574
4 EML4 ALK FUSION GENE 484 82% 2% 281
5 DNA REPAIR GENES 348 59% 4% 394
6 XPD POLYMORPHISMS 309 90% 1% 137
7 XPD 296 79% 2% 189
8 PREVIOUSLY TREATED PATIENTS 289 50% 4% 415
9 CISPLATIN PLUS GEMCITABINE 237 69% 2% 201
10 FACTOR RECEPTOR MUTATIONS 237 67% 2% 212

Journals


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 LUNG CANCER 196 21% 8% 845
2 JOURNAL OF THORACIC ONCOLOGY 172 25% 5% 592
3 CLINICAL LUNG CANCER 78 32% 2% 206
4 THORACIC CANCER 5 12% 0% 44
5 TARGETED ONCOLOGY 4 11% 0% 34

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer 2015 6 45 100%
Acquired resistance to TKIs in solid tumours: learning from lung cancer 2014 36 68 85%
Epidermal growth factor receptor mutations in lung cancer 2007 958 165 52%
Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistant Disease 2013 87 94 81%
Impact of EGFR Inhibitor in Non-Small Cell Lung Cancer on Progression-Free and Overall Survival: A Meta-Analysis 2013 83 44 82%
Future options for ALK-positive non-small cell lung cancer 2015 3 50 92%
ALK in Lung Cancer: Past, Present, and Future 2013 76 39 87%
American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer 2009 350 150 84%
Ceritinib (LDK378): A Potent Alternative to Crizotinib for ALK-Rearranged Non-Small-Cell Lung Cancer 2015 3 24 88%
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer 2010 299 158 72%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 THORAC ONCOL 78 20% 3.0% 342
2 GUANGDONG LUNG CANC 69 62% 0.6% 72
3 LOWE THORAC ONCOL 49 49% 0.6% 73
4 THORAC ONCOL SERV 45 45% 0.7% 77
5 THORAC ONCOL UNIT 26 41% 0.4% 48
6 MED OVARIAN CANC SECT 23 79% 0.1% 15
7 ONCOL PULM UNIT 1 21 85% 0.1% 11
8 PANGAEA BIOTECH 19 76% 0.1% 13
9 MULTIDISCIPLINARY THORAC ONCOL PROGRAM 19 39% 0.3% 38
10 THORAC ONCOL PROGRAM 18 28% 0.5% 55

Related classes at same level (level 2)


Rank Relatedness score Related classes
1 0.0000016801 STEREOTACTIC BODY RADIOTHERAPY//4D CT//STEREOTACTIC BODY RADIATION THERAPY
2 0.0000016624 LUNG CANCER//THORAC SURG//TRANSBRONCHIAL NEEDLE ASPIRATION
3 0.0000014398 HER 2//TRASTUZUMAB//LAPATINIB
4 0.0000011323 CHEMOTHERAPY INDUCED PERIPHERAL NEUROPATHY//VINFLUNINE//VINCRISTINE
5 0.0000011026 SMALL CELL LUNG CANCER//BOMBESIN//GASTRIN RELEASING PEPTIDE
6 0.0000010380 HAND FOOT SYNDROME//RADIATION RECALL//EXTRAVASATION
7 0.0000009990 HEPATOCYTE GROWTH FACTOR//C MET//HGF
8 0.0000009312 DIHYDROPYRIMIDINE DEHYDROGENASE//5 FLUOROURACIL//THYMIDINE PHOSPHORYLASE
9 0.0000008975 CAMPTOTHECIN//SN 38//TOPOTECAN
10 0.0000008666 BRAIN METASTASES//WHOLE BRAIN RADIOTHERAPY//NEOPLASTIC MENINGITIS